NASDAQ:VRDN

Viridian Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VRDN

*Your capital is at risk

$19.74

-0.460 (-2.28%)

At Close: Jul 10, 2026

Viridian Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.17. In total, the insiders bought 9.98M and sold 31.01K VRDN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.17
● Buy	9.98M shares
● Sell	31.01K shares
91% Buy Activity Weak Positive Correlation
Buy Signal High Confidence May 11, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.17. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (91% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Morris Arlene Director	Director	32 341 Value: $597.7K
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Kiselak Tomas Director	Director	32 341 Value: $597.7K
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Gheuens Sarah Director	Director	32 341 Value: $597.7K
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Moses Jennifer K. Director	Director	32 341 Value: $597.7K
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Cain Christopher W. Director	Director	32 341 Value: $597.7K
Jul 01, 2026 Buy	Stock Option (Right to Buy) A-Award	Ajer Jeffrey Robert Director	Director	32 341 Value: $597.7K
May 11, 2026 Buy	Common Stock P-Purchase	Fairmount Funds Management Llc	Director	1 176 470 Value: $20.0M
Mar 03, 2026 Sell	Common Stock F-InKind	Tousignant Jennifer Chief Legal Officer	Officer	1 675 Value: $50.6K
Mar 03, 2026 Sell	Common Stock F-InKind	Beetham Thomas W. Chief Operating Officer	C-Suite Officer	3 048 Value: $92.0K
Mar 03, 2026 Sell	Common Stock F-InKind	Harmon Seth Chief Financial Officer	C-Suite Officer	2 031 Value: $61.3K
Mar 03, 2026 Sell	Common Stock F-InKind	Mahoney Stephen F. President And CEO	CEO / President	7 408 Value: $223.6K
Mar 03, 2026 Buy	Common Stock M-Exempt	Mahoney Stephen F. President And CEO	CEO / President	18 357 Value: $538.2K
Mar 03, 2026 Sell	Common Stock F-InKind	Beetham Thomas W. Chief Operating Officer	C-Suite Officer	3 138 Value: $92.0K
Mar 03, 2026 Buy	Common Stock M-Exempt	Beetham Thomas W. Chief Operating Officer	C-Suite Officer	9 409 Value: $275.9K
Mar 03, 2026 Sell	Common Stock F-InKind	Tousignant Jennifer Chief Legal Officer	Officer	1 724 Value: $50.5K
Mar 03, 2026 Buy	Common Stock M-Exempt	Tousignant Jennifer Chief Legal Officer	Officer	5 169 Value: $151.6K
Mar 03, 2026 Buy	Restricted Stock Units M-Exempt	Tousignant Jennifer Chief Legal Officer	Officer	5 169 Value: $151.6K
Mar 03, 2026 Buy	Restricted Stock Units M-Exempt	Harmon Seth Chief Financial Officer	C-Suite Officer	6 267 Value: $183.7K
Mar 03, 2026 Buy	Common Stock M-Exempt	Harmon Seth Chief Financial Officer	C-Suite Officer	6 267 Value: $183.7K
Mar 03, 2026 Sell	Common Stock F-InKind	Harmon Seth Chief Financial Officer	C-Suite Officer	2 091 Value: $61.3K
Mar 03, 2026 Buy	Restricted Stock Units M-Exempt	Beetham Thomas W. Chief Operating Officer	C-Suite Officer	9 409 Value: $275.9K
Mar 03, 2026 Buy	Restricted Stock Units M-Exempt	Mahoney Stephen F. President And CEO	CEO / President	18 357 Value: $538.2K
Mar 03, 2026 Sell	Common Stock F-InKind	Mahoney Stephen F. President And CEO	CEO / President	7 627 Value: $223.6K
Mar 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Tripuraneni Radhika Chief Medical Officer	Officer	95 800 Value: $2.90M
Mar 02, 2026 Buy	Restricted Stock Units A-Award	Mahoney Stephen F. President And CEO	CEO / President	111 900 Value: $3.38M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VIRIDIAN THERAPEUTICS, INC.

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...

Read Full Profile Here